Description
Introduction
Cephalosporin drug are largely antibiotics which have been derived from Acremonium. It yielded three components Cephalosporin N, C and P which lead to the first productions of Cephalosporins. These work in a way similar to Penicillin by binding and blocking the activity of enzymes which are responsible for peptidoglycan. Peptidoglycan is a crucial component of the bacterial cell wall. Cephalosporin Drugs are used to treat a variety of bacterial infections, the most common are respiratory tract infections, urinary tract infections, skin infection etc.
There are different types of Cephalosporin Drugs available in the market are cephalosporins/beta-lactamase inhibitors, first generation cephalosporins, fourth generation cephalosporins, next generation cephalosporins, second generation cephalosporins, third generation cephalosporins. The drug’s adverse reactions are quite un common (>1% patients). The reactions include: diarrhea, nausea, rash, electrolyte disturbances, and pain.
Market Dynamics
The increase in Research and development in the pharmaceutical industry across various countries has been a key driver in the growth of this industry. The increase in demand of anti-bacterial drugs for various diseases also fueled its growth. However, the amount of investment in Research and Development doesn’t fetch it the right amount of revenue hence, it acts as a hindrance to its growth.
Market Segmentation
The Market for the Cephalosporin Drugs has been segmented on the basis of route of administration like oral or injected. It also segmented on the basis of type such as branded or generic. But largely it is segmented on the basis of spectrum of anti-microbial activity i.e. First generation, Second Generation, Third Generation, Fourth and Fifth Generation.
Regional/Geographic Analysis
The United States and Canada in North America; China, Japan, India in Asia-Pacific; Germany, UK, France, Italy and Russia in Europe; Brazil in South America have the largest market in their respective regions.
Key Players
Some of the major players in the market include Astellas, Lupin Pharmaceuticals, Bristol-Myers Squibb, Glaxo SmithKline, Roche, Ranbaxy, Merck, Pfizer, Sandoz,Teva Pharmaceuticals.
- Market segments
- Market Drivers, Restraints and Opportunities
- Market Size & Forecast 2016 to 2022
- Supply & Demand Value Chain
- Market – Current Trends
- Competition & Major Companies
- Technology and R&D Status
- Porters Five Force Analysis
- Strategic and Critical Success Factor Analysis of Key Players
- North America
- US and Canada
- Latin America
- Mexico, Brazil, Argentina and Rest of Latin America
- Western Europe
- EU5 (Germany, France, Italy, Spain, U.K.)
- Nordic Countries (Denmark, Finland, Norway, and Sweden)
- Benelux (Belgium, The Netherlands, and Luxembourg)
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Rest of Eastern Europe
- Asia Pacific
- China
- India
- Japan
- Australia and New Zealand
- Rest of Asia Pacific
- Middle East and Africa
- GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
- South Africa
- North Africa
- Rest of Middle East and Africa
This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides details on market segmentation which is derived from several product mapping exercises, macroeconomic parameters and other qualitative and quantitative insights. The impact of all such factors is delivered across multiple market segments and geographies.
- Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
- Consumer and Pricing Analysis
- Market dynamics of the industry
- Market Segmentation
- Estimated Market Sizing in terms of volume and value
- Recent trends in Market and impact
- Research Status and Technology Overview
- Extensive Industry Structure Coverage
